Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;120(2):275-90.
doi: 10.1007/s00702-012-0893-9. Epub 2012 Sep 25.

Immunogenicity of botulinum toxins

Markus Naumann  1 , Lee Ming Boo, Alan H Ackerman, Conor J Gallagher
Affiliations
Review

Immunogenicity of botulinum toxins

Markus Naumann et al. J Neural Transm (Vienna). 2013 Feb.

Abstract

Botulinum neurotoxins are formulated biologic pharmaceuticals used therapeutically to treat a wide variety of chronic conditions, with varying governmental approvals by country. Some of these disorders include cervical dystonia, post-stroke spasticity, blepharospasm, migraine, and hyperhidrosis. Botulinum neurotoxins also have varying governmental approvals for cosmetic applications. As botulinum neurotoxin therapy is often continued over many years, some patients may develop detectable antibodies that may or may not affect their biological activity. Although botulinum neurotoxins are considered "lower risk" biologics since antibodies that may develop are not likely to cross react with endogenous proteins, it is possible that patients may lose their therapeutic response. Various factors impact the immunogenicity of botulinum neurotoxins, including product-related factors such as the manufacturing process, the antigenic protein load, and the presence of accessory proteins, as well as treatment-related factors such as the overall toxin dose, booster injections, and prior vaccination or exposure. Detection of antibodies by laboratory tests does not necessarily predict the clinical success or failure of treatment. Overall, botulinum neurotoxin type A products exhibit low clinically detectable levels of antibodies when compared with other approved biologic products. This review provides an overview of all current botulinum neurotoxin products available commercially, with respect to the development of neutralizing antibodies and clinical response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med. 1992;85:524–529. - PMC - PubMed
    1. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–29. doi: 10.1046/j.1468-1331.2001.00035.x. - DOI - PubMed
    1. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S68–S84. doi: 10.1002/mds.20020. - DOI - PubMed
    1. Atassi MZ (2006) On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 152(Pt 7):1891–1895; discussion 1895–1897 - PubMed
    1. Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008;45:3878–3888. doi: 10.1016/j.molimm.2008.06.031. - DOI - PubMed

Publication types